WASHINGTON STATE CONVENTION CENTER

February 13–16, 2017

Conference Dates and Location: 
February 23-26, 2015 | Seattle, Washington
Abstract Number: 
143LB

Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate

Author(s): 

Paul E. Sax7, Michael S. Saag2, Michael T. Yin3, Frank A. Post4, Shinichi Oka8, Ellen Koenig5, Benoit Trottier9, Jaime Andrade-Villanueva6, Huyen Cao1, Marshall W. Fordyce1
1 Clinical Research, Gilead Sciences Inc, Foster City, CA, United States. 2 University of Alabama at Birmingham, Birmingham, AL, United States. 3 College of Physicians and Surgeons, Columbia University, New York, NY, United States. 4 King's College Hospital, London, United Kingdom. 5 Dominican Institute for Virologic Studies, Santo Domingo, Dominican Republic. 6 Unidad de VIH del Hospital Civil de Guadalajara, Guadalajara, Mexico. 7 Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States. 8 National Center for Global Health and Medicine, Japan, Tokyo, Japan. 9 Clinique Medicale l'Actuel, Montreal, QC, Canada.

Abstract Body: 

Background: Off-target renal and bone side effects may occur with tenofovir disoproxil fumarate (TDF) use. Compared with TDF, tenofovir alafenamide (TAF) results in significantly reduced plasma tenofovir (TFV) and may have less renal and bone toxicity.

Methods: Treatment naïve HIV-1+ adults were randomized 1:1 to a single tablet regimen of E/C/F/TAF or E/C/F/TDF once daily in two double blind studies. Assessments included measures of renal function and bone mineral density (BMD). Four pre-specified secondary safety endpoints were tested: serum creatinine, treatment-emergent proteinuria, spine and hip BMD. Week 48 off-target side effects data are described.

Results: Combined, the two studies randomized and treated 1,733 subjects. Plasma TFV was >90% lower (mean [%CV] AUCtau 297 (20) vs. 3,410 (25) nghr/mL) in the E/C/F/TAF arm, compared to the E/C/F/TDF arm. Serum creatinine (mean [SD] change: +0.08 [0.124] vs +0.11 [0.217] mg/dL, p<0.001), quantified proteinuria (UPCR, median [Q1, Q3] % change; -3 [-35, +43] vs +20 [-23, +76], p<0.001), albuminuria (UACR, median [Q1, Q3] % change; -5 [-33, +36] vs +7 [-27, +62], p=0.001), retinol binding protein (RBP:Cr, median [Q1, Q3] % change; +9 [-23, +49] vs +51 [+3, +133]), beta-2-microglobulin (β-2-Mg:Cr, median [Q1, Q3] % change; -32 [-57, +4] vs +24 [-34, +168]), and fractional excretion of phosphate (median [Q1, Q3] % change; +0.9 [-2.0, +4.5] vs +1.7 [-1.6, +5.3]), all favored E/C/F/TAF. There were no cases of proximal tubulopathy in either arm. Mean (SD) % decrease in BMD was significantly less in the E/C/F/TAF arm for both lumbar spine (-1.30 [3.08] vs -2.86 [3.25], p<0.001) and total hip (-0.66 [3.26] vs -2.95 [3.41], p<0.001). Increases from baseline in bone turnover biomarkers (C-telopeptide and P1NP) and parathyroid hormone were significantly smaller in the E/C/F/TAF group compared with the E/C/F/TDF arm (p < 0.001 for all). Increases in fasting lipid parameters (total cholesterol, HDL, direct LDL, and triglycerides) were greater in the E/C/F/TAF arm (p < 0.001 for all).

Conclusions: Through 48 weeks, subjects receiving E/C/F/TAF had significantly better outcomes related to renal and bone health than those treated with E/C/F/TDF; lipid outcomes favored E/C/F/TDF. Collectively these data demonstrate important safety benefits of TAF relative to TDF, especially given the aging of the HIV population and the need for long-term treatment.

Session Number: 
O-11
Session Title: 
Cardiovascular, Bone, and Kidney Health
Presenting Author: 
Sax, Paul
Presenter Institution: 
Brigham and Women's Hospital and Harvard Medical School
Poster: 
Poster to be submitted.